Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd demonstrates a promising future driven by its innovative RNA medicines platform, PRISM, which integrates diverse modalities and chemistry innovations for the treatment of both rare and prevalent diseases. The acceleration of regulatory engagement for key products, such as WVE-006 for alpha-1 antitrypsin deficiency and the anticipated NDA submission for WVE-N531 targeting Duchenne muscular dystrophy, suggests strong potential for future revenues and enhanced market positioning. Management's proactive adjustments in economic assumptions and optimism regarding therapeutic effects signal an increasing confidence in the company's long-term growth trajectory and overall value proposition.

Bears say

WAVE Life Sciences Ltd has reported a substantial net loss of $53.2 million in 4Q25, accompanied by significant research and development expenses of $53 million during the same period, indicating financial strain. The company faces multiple risks related to the clinical trials of its lead programs, WVE-004 and WVE-N531, including potential failures in achieving regulatory approval and commercial revenue projections, which could further hinder its financial stability. Additionally, the challenging financing environment in the biotechnology sector and a crowded competitive landscape for RNA-targeting therapies could impair WAVE's market success and ability to secure necessary funding for product launches.

WVE has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 12 analysts, WVE has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.